Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 9, 2022
Data from additional patients in the TakeAim Leukemia trial of emavusertib to be presented during ASH 2022 Curis focuses its resources to drive the development of emavusertib Cash runway extended...
-
Nov 7, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company along with its collaborative...
-
Nov 2, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third...
-
Oct 7, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 3, 2022, the independent...
-
Oct 3, 2022
Symposium hosted by Guillermo Garcia-Manero, M.D.; Hagop Kantarjian, M.D.; Amit Verma, M.B.B.S. Academics and industry professionals will gather virtually on October 7, 2022 LEXINGTON, Mass., Oct....